Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Rheumatoid arthritis (RA) involves pro-inflammatory macrophages.
• Methotrexate (MTX) is a key RA treatment, but its anti-inflammatory mechanisms are unclear.
• MTX efficacy is linked to specific macrophage subtypes.

Purpose of the Study:

• To elucidate the molecular mechanisms of MTX's anti-inflammatory action in macrophages.
• To investigate MTX's effects on toll-like receptor (TLR) and tumor necrosis factor receptor (TNFR) signaling.
• To identify potential biomarkers for MTX response in RA.

Main Methods:

• Quantitative real-time PCR, western blot, and ELISA were used to analyze macrophage responses.
• siRNA-mediated knockdown was employed to assess gene function.
• In vivo studies included MTX-treated arthritis patients and a murine sepsis model.

Main Results:

• MTX induced macrophage tolerance, reducing IL-6 and IL-1β production.
• MTX attenuated inflammatory signaling pathways (MAPK, NF-κB, TRIF1).
• MTX increased A20 (TNFAIP3) expression, crucial for MTX-induced tolerance; A20 was upregulated in MTX-responsive patients.

Conclusions:

• MTX exerts anti-inflammatory effects by upregulating A20 expression in macrophages.
• A20-mediated innate tolerance may mitigate RA inflammation.
• A20 is a potential biomarker for predicting MTX response in RA.